Objective: We investigated whether free 25(OH)D concentrations differ according to use of HC.
status (6, 7) . In the circulation, approximately 85% to 90% of 25(OH)D is bound to vitamin D-binding protein (DBP) and 10% to 15% is bound to albumin, so that ,1% of serum 25(OH)D is unbound or free (8) (9) (10) . According to the "free hormone hypothesis," only the free fractions of hormones may be biologically active (10) . Therefore, it has been discussed that free 25(OH)D levels might be a more accurate biomarker of vitamin D status than is total 25(OH)D, although the biological relevance of free 25(OH)D still needs to be clarified (10) .
Although DBP concentrations are, in general, intraindividually relatively stable, certain conditions substantially increase (e.g., high estrogen levels in pregnancy) or decrease (e.g., liver cirrhosis or nephrotic syndrome) DBP levels and may thus affect total and free 25(OH)D concentrations (8) (9) (10) . Use of hormonal contraceptives (HC) has in most, but not all, studies been associated with higher DBP and higher total 25(OH)D concentrations, whereas the effect of HC on free 25(OH)D levels is largely unknown (9, (11) (12) (13) (14) (15) (16) (17) (18) . Considering that roughly 50% of women of childbearing age in Europe and the United States use HC, it is of great importance to evaluate the effect of HC on parameters of vitamin D status (19) . Of particular interest is the research question of whether the HC-associated elevation in total 25(OH)D is associated with a parallel elevation in free 25(OH)D. If only total but not free 25(OH)D is substantially increased by HC use, this could suggest that vitamin D status based on total 25(OH)D concentrations might be overestimated in women taking HC. Moreover, it is interesting to investigate how the association between HC use and total and free 25(OH)D is modified after supplementation of vitamin D.
In this study, we aimed to measure total and free 25(OH)D in apparently healthy women before and after multimicronutrient supplementation with 200 IU or 800 IU of vitamin D3 per day for 8 weeks during wintertime in Germany (15) . From this trial we have already reported that users of HC had significantly higher total 25(OH)D concentrations compared with nonusers (15) . The main aim of the present investigation is to evaluate whether the difference in total 25(OH)D between users and nonusers of HC is paralleled by a similar difference in free 25(OH)D at baseline as well as after vitamin D supplementation.
Methods

Design
This is a post hoc analysis of a single-center, open, parallelgroup randomized controlled trial conducted from 13 January 2016 (first participant in), to 9 May 2016 (last participant out), at a clinical research organization (BioTeSys GmbH) in Esslingen, Germany (15) . Details of the study design, methods, and results have been published previously and adhere to the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement (15, (20) (21) (22) . We obtained ethical approval by the institutional review board of the Landesärztekammer BadenWürttemberg. The trial was sponsored by Merck Selbstmedikation GmbH (Darmstadt, Germany) and was registered at German Clinical Trials Register (http://www.germanctr.de) (DRKS-ID: DRKS00009770).
Participants
We enrolled apparently healthy women age $18 to #45 years with a body mass index (BMI) of 17 to 30 kg/m 2 without any vitamin D supplement intake/prescription in the past 2 months and during the trial. Detailed inclusion and exclusion criteria are published elsewhere (15) . All participants gave written informed consent before inclusion in the trial.
Intervention
Study participants were randomly assigned in a 1:1 ratio to receive a daily multimicronutrient supplement containing 200 IU vitamin D3 (Elevit® 1; lot MA029U8; Bayer Vital GmbH, Leverkusen, Germany) or 800 IU vitamin D3 (Femibion® 1; lot: 488615/090; Merck Selbstmedikation GmbH, Darmstadt, Germany) for 8 weeks (see Supplemental Table 1 for detailed nutrient facts of these two multimicronutrient supplements). Participants were asked whether they take HC regularly; randomization was also stratified for users and nonusers of HC.
Outcome measures
The primary outcome measure was the difference in free 25(OH)D between users and nonusers of HC at baseline and after vitamin D supplementation. The secondary outcomes were differences in total and percentage of free 25 
Measurements
Total serum 25(OH)D was measured as part of the original study by liquid chromatography-tandem mass spectrometry using the MassChrom 25-OH-Vitamin D3/D2 kit (Chromsystems GmbH, Gräfelfing, Germany) (15) . Interassay coefficients of variation were 5.5% (at a level of 95.8 nmol/L) and 6.7% (at 42.4 nmol/L), respectively. Free 25(OH)D was measured in a subgroup of study participants who gave informed consent for further research use of their stored samples. These serum samples were continuously stored at 270°C from the respective study visit (January to May 2016) until analysis at BioTeSys (Esslingen, Germany) in December 2017. Serum free 25(OH)D was determined with a well-validated commercially available competitive enzyme-linked immunosorbent assay kit developed by DIAsource ImmunoAssays (Louvain-la-Neuve, Belgium) and Future Diagnostics Solutions (Wijchen, the Netherlands) (14, (23) (24) (25) (26) . Intra-assay coefficient of variation was 1.5%. Vitamin D intake was assessed by a 3-day food diary protocol as described previously (15) . In addition, participants were asked whether they participate in sports regularly, whether they are active smokers, and how many minutes per day they were on average exposed to sunlight during the 4 weeks before the screening visit.
Data analysis
Continuous data following a normal distribution are shown as means with standard deviations, and parameters with a skewed distribution are shown as medians with interquartile ranges. Categorical data are presented as percentages. Where appropriate, skewed variables were log(e) transformed before they were used in parametric analyses.
Comparisons between users and nonusers of HC, as well as between intervention groups, were calculated by a Wilcoxon rank-sum test because most parameters did not follow a normal distribution or by a x 2 test. Differences in total, free, and percentage of free 25(OH)D between users and nonusers of HC were also calculated with analysis of covariance with adjustment for age and BMI because these covariates are usually associated with 25(OH)D levels. Between-group differences in D changes of outcome parameters were calculated by Wilcoxon rank-sum test and within-group changes by Wilcoxon signedrank test. Pairwise Spearman correlation analyses between total 25(OH)D, free 25(OH)D, and the percentage of free 25(OH)D were performed. A P value , 0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed by using SPSS software, version 24.0 (IBM, Chicago, IL), and GraphPad Prism software, version 5.04 (GraphPad Software, La Jolla, CA).
Results
From the 201 study participants who were randomly assigned to 200 IU (n = 100) or 800 IU (n = 101) of vitamin D3 daily for 8 weeks, 196 completed the trial. Of these, 176 participants gave their informed consent for further research use of their serum samples. The present investigation is restricted to these 176 participants in whom we could measure serum free 25(OH)D (see Supplemental Fig. 1 for participant flowchart) .
Baseline characteristics of the 176 participants as well as for users and nonusers of HC are shown in Table 1 . Users of HC included participants with oral contraceptives (n = 94), hormone-releasing vaginal rings (n = 15), and gestagen injection (n = 1). In brief, users of HC were slightly younger and had significantly higher total 25(OH)D but lower percentage of free 25(OH)D levels compared with nonusers of HC, whereas there was no significant difference in free 25(OH)D according to hormone use ( Figs. 1 and 2) . The difference in total 25(OH)D and percentage of free 25(OH)D between users and nonusers of HC remained significant after adjustment for age and BMI (P , 0.001 for both), but there was again no difference in free 25(OH)D (P = 0.683).
Baseline characteristics (the same as in Table 1 ) did not significantly differ between the treatment groups when stratified by use or nonuse of HC (Supplemental Table 2 ). Serum concentrations of total, free, and percentage of free 25(OH)D at baseline and follow-up and stratified by use and nonuse of HC, as well as stratified by treatment group, are presented in Table 2 . Within-treatment group changes from baseline to follow-up after 8 weeks of vitamin D3 supplementation for total, free, and percentage of free 25(OH)D in all participants and stratified by use and nonuse of HC are shown in Table 3 .
Pairwise Spearman correlation coefficients between total, free, and percentage of free 25(OH)D at baseline and follow-up for all study participants as well as for users and nonusers of HC are shown in Table 4 .
At follow-up, analyses stratified by treatment group revealed that the differences in total and percentage of free 25(OH)D remained significant between users and nonusers of HC (P , 0.005 for all), with no difference in free 25(OH)D concentrations (P . 0.5 for all; see also Table 2 ). Our results remained materially unchanged when we excluded participants with hormone-release vaginal ring and gestagen injection from the HC group (data not shown).
Discussion
In this study in apparently healthy women we showed that use of HC was associated with higher 25(OH)D concentrations whereas free 25(OH)D was similar in users and nonusers of HC. These findings were consistent, at baseline, after multimicronutrient supplementation and in subgroups according to treatment allocation.
Data on HC and free 25(OH)D are considered an "area of uncertainty" as recently reviewed by Bikle et al. (10) . Our study specifically addressed the relationship between HC use and directly measured free 25(OH)D in a randomized vitamin D trial. In a previous investigation in healthy blood donors, however, Oleröd et al. (14) already reported data in a few (number not indicated, but not more than 24 participants) premenopausal women using HC. Compared with nonusers of HC, total 25(OH)D was significantly higher, whereas there was only a nonsignificant trend toward higher free 25(OH)D in users of HC (14.3 6 6.1 vs 11.8 6 4.1 pmol/ L; P = 0.076) (14) . Our study significantly adds to these preliminary results by clearly showing at baseline and after vitamin D supplementation that only total, not free, 25(OH)D is increased in users vs nonusers of HC.
The underlying physiologic mechanism for our findings may, at least in part, be explained by an estrogeninduced increase of liver-derived DBP in HC users, a finding that has been reported previously (9, 10, 13, 14) . This HC-induced increase in DBP levels may hypothetically lead to an increased binding of 25(OH)D and may thus reduce free 25(OH)D concentrations. This fits well with previous findings of no correlation between DBP and free 25(OH)D levels, suggesting that the increase in total 25(OH)D that is induced by higher DBP concentrations is not accompanied by a similar increase in free 25(OH)D (26) . However, other effects of HC, such as modulation of the activity of vitamin D hydroxylases, may hypothetically also play a role in the effect of HC on total and free 25(OH)D concentrations (27, 28) . Regarding the general association between total and free 25(OH)D, we confirm previous investigations showing that their correlation is attenuated at higher 25(OH)D levels, with a subsequently negative correlation between total 25(OH)D and percentage of free 25(OH) D (Table 4) (14) .
Although mechanistic explanations for our results remain speculative, it is of great clinical importance to evaluate the net effect of HC use on whole-body vitamin D status or effects. According to the "free hormone hypothesis," only free 25(OH)D may be biologically active by crossing the plasma membrane because of its lipophilic properties followed by intracellular conversion to 1,25-dihydroxyvitamin D [1,25(OH)2D] and then binding to the intracellular located vitamin D receptor (VDR) (10) . A few organs that are crucial for vitamin D effects, such as the kidneys and maybe also the parathyroid glands and placenta are, however, able to take up DBP-bound vitamin D metabolites through endocytosis by the megalin/cubilin complex (10) . The relative contribution of both manners of cellular uptake of vitamin D metabolites is not known, but the VDR is almost ubiquitously present and most cells do not express the megalin/cubilin complex (10) . In line with the "free hormone hypothesis," some experimental studies indicate that VDR activation is attenuated when DBP is added to the serum and likewise reduces free 25(OH)D levels without altering total 25(OH)D concentrations (8) . Furthermore, data comparing users and nonusers of HC do not show significant changes in, for example, parathyroid hormone, which usually decreases with higher 25(OH)D levels; this supports the hypothesis that the increase in total 25(OH)D by HC may not have major effects on whole body's vitamin D status (13) . Consequently, it has been postulated that measuring free 25(OH)D may better measure vitamin D status than does measuring total 25(OH)D concentrations, but clinical data on this topic are inconclusive at present (10, (29) (30) (31) . However, in most individuals, total and free 25(OH)D concentrations are significantly correlated and DBP levels are usually intraindividually relatively stable over time (8, 10, 14) . Therefore, total 25(OH)D levels usually provide a good estimate of free 25(OH)D levels, except under conditions with likewise significantly reduced (e.g., liver cirrhosis or nephrotic syndrome) or increased (e.g., pregnancy or intake of HC) DBP levels (10). Our findings on consistently similar free 25(OH)D levels in users vs nonusers of HC but approximately on average 26% higher total 25(OH)D levels in HC users suggest that we might overestimate whole-body vitamin D status in women taking HC.
Given that in western countries approximately every second woman in the reproductive age is taking HC, our findings may have important implications for individual and epidemiological data on the prevalence of vitamin D deficiency (16) . The physiological implications of our findings are, however, largely unclear. In this context, it must be considered that free 1,25(OH)2D concentrations are similar or may even be higher than free 25(OH)D concentrations, suggesting a relatively minor effect of free 25(OH)D compared with free 1,25(OH)2D (8) (9) (10) . Therefore, the biological relevance of the free hormone hypothesis should not be uncritically accepted for free Values are median (interquartile range). Within group changes from baseline to follow up were calculated by Wilcoxon signed-rank test. All within-group changes except those marked were significant at P , 0.001. a P = 0.008.
25(OH)D.
Moreover, uptake of vitamin D metabolites into target cells depends not only on their free circulating concentrations but also on other factors, such as dissociation from binding proteins, cellular uptake rates, blood flow, and further intracellular metabolism (8) (9) (10) . Current knowledge on these factors is, however, still incomplete. Our data are limited because our results on the association between HC use and free 25(OH)D are only observational and are not derived from a randomized controlled trial of HC. Furthermore, we do not have additional measurements of vitamin D and mineral metabolism, such as DBP, parathyroid hormone, 1,25(OH)2D, or serum calcium. Another drawback of our study is the lack of more detailed information on the specific HC used by the study participants. On the other hand, we consider it a strength of our study that we directly measured free 25(OH)D, because previous investigations indicate some flaws of calculated free 25(OH)D based on total 25(OH)D, albumin and DBP (14, (24) (25) (26) 31) . The consistency of our findings at baseline, after multimicronutrient supplementation and in subgroups according to treatment allocation, strongly underscores the validity of our results.
In conclusion, we have shown that HC use is associated with higher total 25(OH)D concentrations whereas free 25(OH)D levels are similar in users vs nonusers of HC. The clinical significance of these HC-induced changes in vitamin D metabolites must be further elucidated, but it could be hypothesized that vitamin D status based on total 25(OH)D concentrations might be overestimated in HC users. This notion points toward a possible clinical impact of our findings given that in western countries approximately every second woman of reproductive age is taking HC. 
